Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi Succeeds In Canadian Adalimumab Tussle

Court Order Provides For Immediate Marketing Authorization

Executive Summary

Fresenius Kabi has been forced to wait to gain a Notice of Compliance, effectively a marketing authorization, for its Idacio (adalimumab) biosimilar to Humira in Canada, in light of the Minister of Health’s interpretation of regulatory language. However, a Federal Court has now found that earlier decisions by the Ministry barring approval were unreasonable.

You may also be interested in...



Sandoz Confirms Launch Of Humira Rival In Canada

Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.

What’s Next? Five Things To Look Out For In February

In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel